Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-27T06:19:44.008Z Has data issue: false hasContentIssue false

Chapter 18 - Anxiety Disorders

Published online by Cambridge University Press:  01 February 2024

By
Eleonora Piccoli ,
Simone Vanzetto ,
Lucia Cerolini ,
Dario Conti ,
Laura Celebre  and
Bernardo Dell’Osso
Edited by
Andrea Fiorillo ,
Peter Falkai  and
Philip Gorwood
Andrea Fiorillo
Affiliation:
University of Campania “L. Vanvitelli”, Naples
Peter Falkai
Affiliation:
Ludwig-Maximilians-Universität München
Philip Gorwood
Affiliation:
Sainte-Anne Hospital, Paris
Get access

Summary

Anxiety Disorders (ADs) are the most prevalent mental disorders worldwide and are characterized by a wide variety of psychological and somatic symptoms, which are often misinterpreted as symptoms of a medical condition. ADs carry a large disease burden that impacts negatively on patients’ health-related quality of life and global life satisfaction and disrupts important activities of daily living. In this chapter we analyze the epidemiology and clinical presentation of ADs, highlighting recent innovations and changes in the classification of anxiety disorders in DSM-5 and ICD-11. Main available pharmacological and nonpharmacological therapies for the treatment of ADs, based on the most recent clinical evidence and updated literature, are presented as well. Lastly, we focus the attention on future perspectives about ADs, examining clinical correlations of peripheral biomarkers, neuroimaging, genetics, epigenetics, and microbiota data. These features may be useful to achieve further insight in terms of physiopathology, to support early diagnosis, and to facilitate the prediction of illness susceptibility and treatment response, in order to support clinicians’ practice and to develop personalized treatment strategies.

Keywords

anxiety disorderspanic disordergeneralized anxiety disordersocial anxiety disordergeneticsneuroimagingpsychopharmacology
Type
Chapter
Information
Mental Health Research and Practice
From Evidence to Experience
 , pp. 317 - 340
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association/DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. American Psychiatric Association; 2013. www.worldcat.org/title/diagnostic-and-statistical-manual-of-mental-disorders-dsm-5/oclc/830807378.Google Scholar
Penninx, BW, Pine, DS, Holmes, EA, Reif, A. Anxiety disorders. Lancet 2021;397(10277):914–27. www.thelancet.com/article/S0140673621003597/fulltext.CrossRefGoogle ScholarPubMed
Park, SC, Kim, YK. Anxiety disorders in the DSM-5: Changes, controversies, and future directions. Adv Exp Med Biol 2020;1191:187–96.CrossRefGoogle ScholarPubMed
Asmundson, GJG, Taylor, S, Smits, JAJ. Panic disorder and agoraphobia: An overview and commentary on DSM-5 changes. Depress Anxiety 2014;31(6):480–6.CrossRefGoogle ScholarPubMed
World Health Organization. ICD-11 – Mortality and Morbidity Statistics 2019. https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/831337417.Google Scholar
World Health Organization. ICD-10 online versions. 2019; https://icd.who.int/browse10/2019/en.Google Scholar
Gaebel, W, Kerst, A. ICD-11 Mental, behavioural or neurodevelopmental disorders: Innovations and managing implementation. Arch Psychiatry Psychother 2019;21(3):7–12.CrossRefGoogle Scholar
Reed, GM, First, MB, Kogan, CS, et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry 2019;18(1):3–19.CrossRefGoogle ScholarPubMed
Kogan, CS, Stein, DJ, Maj, M, et al. The classification of anxiety and fear-related disorders in the ICD-11. Depression and Anxiety 2016;33(12):1141–54.CrossRefGoogle ScholarPubMed
Remes, O, Brayne, C, van der Linde, R, Lafortune, L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav 2016;6(7):e00497. https://doi.org/10.1002/brb3.497. PMID: 27458547; PMCID: PMC4951626.CrossRefGoogle ScholarPubMed
Baxter, AJ, Scott, KM, Ferrari, AJ, et al. Challenging the myth of an “epidemic” of common mental disorders: Trends in the global prevalence of anxiety and depression between 1990 and 2010. Depress Anxiety 2014;31(6):506–16.CrossRefGoogle ScholarPubMed
OECD. Health at a Glance: Europe 2018 OECD (Health at a Glance: Europe); 2018. www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2018_health_glance_eur-2018-enGoogle Scholar
Wittchen, HU, Jacobi, F, Rehm, J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21(9):655–79.CrossRefGoogle ScholarPubMed
Kessler, RC, Berglund, P, Demler, O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62(6):593–602. https://doi.org/10.1001/archpsyc.62.6.593. Erratum in: Arch Gen Psychiatry 2005;62(7):768. Merikangas, KR [added]. PMID: 15939837.CrossRefGoogle ScholarPubMed
Winkler, P, Formanek, T, Mlada, K, et al. Increase in prevalence of current mental disorders in the context of COVID-19: Analysis of repeated nationwide cross-sectional surveys. Epidemiol Psychiatr Sci 2020;29:e173.CrossRefGoogle ScholarPubMed
Czeisler, M, Lane, RI, Wiley, JF, et al. Follow-up survey of US adult reports of mental health, substance use, and suicidal ideation during the COVID-19 pandemic, September 2020. JAMA Netw Open 2021;4(2):e2037665–e2037665.CrossRefGoogle ScholarPubMed
Wang, Y, Shi, L, Que, J, et al. The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic. Mol Psychiatry 2021; 26: 1–10.CrossRefGoogle Scholar
Huang, Y, Zhao, N. Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 outbreak in China: a web-based cross-sectional survey. Psychiatry Res 2020;288.CrossRefGoogle Scholar
Compton, MT, West, JC, Olfson, M. Prolonged duration of untreated psychosis in nonaffective first-episode psychotic disorders compared to other psychoses. Int J Psychiatry Clin Pract 2006;10(4):265–8. https://pubmed.ncbi.nlm.nih.gov/24941145/.CrossRefGoogle ScholarPubMed
Dell’Osso, B, Camuri, G, Benatti, B, Buoli, M, Altamura, AC. Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: A study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder. Early Interv Psychiatry 2013;7(4):374–80.Google Scholar
Dell’Osso, B, Altamura, AC. Duration of untreated psychosis and duration of untreated illness: New vistas, CNS Spectrums 2010;15(4):238–46. https://pubmed.ncbi.nlm.nih.gov/20414173/.Google ScholarPubMed
Altamura, AC, Dell’Osso, B, Mundo, E, Dell’Osso, L. Duration of untreated illness in major depressive disorder: A naturalistic study. Int J Clin Pract 2007;61(10):1697–700. https://pubmed.ncbi.nlm.nih.gov/17877655/.CrossRefGoogle ScholarPubMed
Altamura, AC, Dell’Osso, B, Vismara, S, Mundo, E. May duration of untreated illness influence the long-term course of major depressive disorder? Eur Psychiatry 2008;23(2):92–6. https://pubmed.ncbi.nlm.nih.gov/18248964/.CrossRefGoogle ScholarPubMed
Dell’Osso, B, Cremaschi, L, Grancini, B, et al. Italian patients with more recent onset of Major Depressive Disorder have a shorter duration of untreated illness. Int J Clin Pract 2017;71(2). https://pubmed.ncbi.nlm.nih.gov/28090727/.Google ScholarPubMed
Galimberti, C, Bosi, MF, Volontè, M, et al. Duration of untreated illness and depression severity are associated with cognitive impairment in mood disorders. Int J Psychiatry Clin Pract 2020;24(3):227–35. https://pubmed.ncbi.nlm.nih.gov/32338553/.CrossRefGoogle ScholarPubMed
Buoli, M, Cesana, BM, Fagiolini, A, et al. Which factors delay treatment in bipolar disorder? A nationwide study focussed on duration of untreated illness. Early Interv Psychiatry 2020;15(5):1136–45. https://pubmed.ncbi.nlm.nih.gov/33058435/.Google ScholarPubMed
Altamura, AC, Buoli, M, Albano, A, Dell’Osso, B. Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: A naturalistic study. Int Clin Psychopharmacol 2010;25(3):172–9. https://pubmed.ncbi.nlm.nih.gov/20305566/.CrossRefGoogle ScholarPubMed
Dell’Osso, B, Benatti, B, Grancini, B, et al. Investigating duration of illness and duration of untreated illness in obsessive compulsive disorder reveals patients remain at length pharmacologically untreated. Int J Psychiatry Clin Pract 2019;23(4):311–13. https://pubmed.ncbi.nlm.nih.gov/31144538/.CrossRefGoogle ScholarPubMed
Matsumoto, Y, Nakamae, T, Abe, Y, Watanabe, A, Narumoto, J. Duration of untreated illness of patients with obsessive–compulsive disorder in Japan. Early Interv Psychiatry 2020;15(6):1644–9. https://pubmed.ncbi.nlm.nih.gov/33372398/.Google ScholarPubMed
Herzog, A, Shedden-Mora, MC, Jordan, P, Löwe, B. Duration of untreated illness in patients with somatoform disorders. J Psychosom Res 2018;107:1–6. https://pubmed.ncbi.nlm.nih.gov/29502757/.CrossRefGoogle ScholarPubMed
Neubauer, K, Weigel, A, Daubmann, A, et al. Paths to first treatment and duration of untreated illness in anorexia nervosa: Are there differences according to age of onset? Eur Eat Disord Rev 2014;22(4):292–8. https://pubmed.ncbi.nlm.nih.gov/24888519/.CrossRefGoogle ScholarPubMed
Buoli, M, Dell’Osso, B, Zaytseva, Y, et al. Duration of untreated illness (DUI) and schizophrenia sub-types: A collaborative study between the universities of Milan and Moscow. Int J Soc Psychiatry 2013;59(8):765–70. https://pubmed.ncbi.nlm.nih.gov/23034286/.CrossRefGoogle ScholarPubMed
Dell’Osso, B, Glick, ID, Baldwin, DS, Altamura, AC. Can long-term outcomes be improved by shortening the duration of untreated illness in psychiatric Disorders? a conceptual framework. Psychopathology; 2012;46(1):14–21. https://pubmed.ncbi.nlm.nih.gov/22890286/.CrossRefGoogle ScholarPubMed
Bukh, JD, Bock, C, Vinberg, M, Kessing, LV. The effect of prolonged duration of untreated depression on antidepressant treatment outcome. J Affect Disord 2013;145(1):42–8. https://pubmed.ncbi.nlm.nih.gov/22854096/.CrossRefGoogle ScholarPubMed
Palazzo, MC, Arici, C, Dell’osso, B, et al. Access and latency to first antipsychotic treatment in Italian patients with schizophrenia and other schizophrenic spectrum disorders across different epochs. Hum Psychopharmacol 2016;31(2):113–20. https://pubmed.ncbi.nlm.nih.gov/26948428/.CrossRefGoogle ScholarPubMed
Dell’Osso, B, Oldani, L, Camuri, G, et al. Reduced duration of untreated illness over time in patients with schizophrenia spectrum, mood and anxiety disorders. Psychiatry Clin Neurosci 2016;70(5):202–10. https://pubmed.ncbi.nlm.nih.gov/26821781/.Google ScholarPubMed
Vigne, P, Fortes, P, Dias, RV, et al. Duration of untreated illness in a cross-diagnostic sample of obsessive-compulsive disorder, panic disorder, and social anxiety disorder. CNS Spectr 2019;24(5):526–32. https://pubmed.ncbi.nlm.nih.gov/30419984/.CrossRefGoogle Scholar
Benatti, B, Camuri, G, Dell’Osso, B, et al. Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder? Int Clin Psychopharmacol 2016;31(6):347–52. https://pubmed.ncbi.nlm.nih.gov/27384739/.CrossRefGoogle ScholarPubMed
Altamura, AC, Santini, A, Salvadori, D, Mundo, E. Duration of untreated illness in panic disorder: a poor outcome risk factor? Neuropsychiatr Dis Treat 2005;1(4):345–7. http://www.ncbi.nlm.nih.gov/pubmed/18568114.Google ScholarPubMed
Wagner, R, Silove, D, Marnane, C, Rouen, D. Delays in referral of patients with social phobia, panic disorder and generalized anxiety disorder attending a specialist anxiety clinic. J Anxiety Disord. 2006;20(3):363–71.CrossRefGoogle ScholarPubMed
Kroenke, K, Spitzer, RL, Williams, JBW, Monahan, PO, Löwe, B. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317–25.CrossRefGoogle ScholarPubMed
Martin-Merino, E, Ruigomez, A, Wallander, M-A, Johansson, S, Garcia-Rodriguez, LA. Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care. Fam Pract. 2010;27(1):9–16.CrossRefGoogle Scholar
Strawn, JR, Welge, JA, Wehry, AM, Keeshin, B, Rynn, MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32(3):149–57.CrossRefGoogle ScholarPubMed
Katzman, MA, Bleau, P, Blier, P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14(1):S1. https://pubmed.ncbi.nlm.nih.gov/25081580/.CrossRefGoogle ScholarPubMed
Bandelow, B, Scott, M, Wedekind, D. Treatment of anxiety disorders. Dialogues Clin Neurosci 2017;19(2):93–107. https://pubmed.ncbi.nlm.nih.gov/28867934/.CrossRefGoogle ScholarPubMed
Bruce, SE, Vasile, RG, Goisman, RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry 2003;160(8):1432–8. https://pubmed.ncbi.nlm.nih.gov/12900305/.CrossRefGoogle ScholarPubMed
Kessler, RC, Wai, TC, Jin, R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(4):415–24.CrossRefGoogle ScholarPubMed
Grancini, B, De Carlo, V, Palazzo, M, et al. Does initial use of benzodiazepines delay an adequate pharmacological treatment? A multicentre analysis in patients with psychotic and affective disorders. Int Clin Psychopharmacol 2018;33(3):140–6. https://pubmed.ncbi.nlm.nih.gov/29461302/.CrossRefGoogle ScholarPubMed
De Carlo, V, Grancini, B, Vismara, M, et al. Exploring characteristics associated with first benzodiazepine prescription in patients with affective disorders and related diagnoses. Hum Psychopharmacol 2019;34(3):e2695. https://pubmed.ncbi.nlm.nih.gov/31044486/.CrossRefGoogle ScholarPubMed
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd ed.). American Psychiatric Association; 1980.Google Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd ed., revised). American Psychiatric Association; 1987.Google Scholar
American Psychiatric Association., Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV. American Psychiatric Association; 1994. 886 p.Google Scholar
Shear, MK, Maser, JD. Standardized assessment for panic disorder research: A conference report. Arch Gen Psychiatry 1994;51(5):346–54. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/496590.CrossRefGoogle ScholarPubMed
Marchesi, C, Cantoni, A, Fontò, S, Giannelli, M, Maggini, C. Predictors of symptom resolution in panic disorder after one year of pharmacological treatment: A naturalistic study. Pharmacopsychiatry 2006;39(2):60–5. https://pubmed.ncbi.nlm.nih.gov/16555166/.CrossRefGoogle ScholarPubMed
Breier, A, Charney, DS, Heninger, GR. Agoraphobia with panic attacks: Development, diagnostic stability, and course of illness. Arch Gen Psychiatry 1986;43(11):1029–36. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/493912.CrossRefGoogle ScholarPubMed
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.). American Psychiatric Association. 2000. https://doi.org/10.1176/appi.books.9780890425596.Google Scholar
World Health Organization(WHO). The ICD-10 classification of mental and behavioural disorders. 1993. https://apps.who.int/iris/handle/10665/37108.Google Scholar
Marks, I. Agoraphobia, panic disorder and related conditions in the DSM-IIIR and ICD-10. J Psychopharmacol. 1987;1(1):6–12. https://doi.org/10.1177/026988118700100103.CrossRefGoogle ScholarPubMed
Wittchen, H, Gloster, A, Beesdo-Baum, K, Fava, G, Craske, M. Agoraphobia: A review of the diagnostic classificatory position and criteria. Depress Anxiety 2010;27(2):113–33. https://pubmed.ncbi.nlm.nih.gov/20143426/.CrossRefGoogle ScholarPubMed
Bystritsky, A, Kerwin, L, Niv, N, et al. Clinical and subthreshold panic disorder. Depress Anxiety 2010;27(4):381.CrossRefGoogle ScholarPubMed
Chou, K-L. Panic disorder in older adults: Evidence from the national epidemiologic survey on alcohol and related conditions. Int J Geriatr Psychiatry 2010;25(8):822–32. https://onlinelibrary.wiley.com/doi/full/10.1002/gps.2424.CrossRefGoogle ScholarPubMed
Horenstein, A, Heimberg, R. Anxiety disorders and healthcare utilization: A systematic review. Clin Psychol Rev 2020;81:101894. https://pubmed.ncbi.nlm.nih.gov/32818687/.CrossRefGoogle ScholarPubMed
Otto, MW, Tuby, KS, Gould, RA, McLean, RYS, Pollack, MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001;158(12):1989–92.CrossRefGoogle ScholarPubMed
Bakker, A, Balkom AJLM, Van, Spinhoven, P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002;106(3):163–7.CrossRefGoogle ScholarPubMed
Moylan, S, Staples, J, Ward, SA, et al. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol. 2011;31(5):647–52.CrossRefGoogle ScholarPubMed
Nardi, AE, Valença, AM, Freire, RC, et al. Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Brazilian J Med Biol Res. 2011;44(4):366–73.CrossRefGoogle ScholarPubMed
Schweizer, E, Pohl, R, Balon, R, et al. Alprazolam in the treatment of panic disorder. Pharmacopsychiatry. 1990;23(02):229–33.CrossRefGoogle ScholarPubMed
Noyes, R, Burrows, GD, Reich, JH, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996;57(8):349–55. http://europepmc.org/abstract/MED/8752017.Google ScholarPubMed
Galynker, I, Khan, A, Grebchenko, Y, et al. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry 2005;66(04):544.CrossRefGoogle ScholarPubMed
Hollifield, M, Thompson, PM, Ruiz, JE, Uhlenhuth, EH. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety. 2005;21(1):33–40.CrossRefGoogle ScholarPubMed
Simon, NM, Hoge, EA, Fischmann, D, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 2006;67(03):381–5.CrossRefGoogle ScholarPubMed
Prosser, JM, Yard, S, Steele, A, Cohen, LJ, Galynker, II. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. BMC Psychiatry 2009;9(1):25.CrossRefGoogle ScholarPubMed
Perna, G, Caldirola, D. Management of treatment-resistant panic disorder. Curr Treat Options Psychiatry 2017;4(4):371–86. https://link.springer.com/article/10.1007/s40501-017-0128-7.Google ScholarPubMed
Hofmann, SG, Smits, JAJ. Cognitive-behavioral therapy for adult anxiety disorders: A meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008;69(4):621–32. https://pubmed.ncbi.nlm.nih.gov/18363421/.Google ScholarPubMed
Sánchez-Meca, J, Rosa-Alcázar, AI, Marín-Martínez, F, Gómez-Conesa, A. Psychological treatment of panic disorder with or without agoraphobia: A meta-analysis. Clin Psychol Rev 2010;30(1):37–50.CrossRefGoogle ScholarPubMed
Muris, P, van Brakel AML, , Arntz, A, Schouten, E. Behavioral inhibition as a risk factor for the development of childhood anxiety disorders: A longitudinal study. J Child Fam Stud 2011;20(2):157–70.CrossRefGoogle ScholarPubMed
Furukawa, TA, Watanabe, N, Churchill, R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev 2007;1:CD004364.Google Scholar
Crocq, M. The history of generalized anxiety disorder as a diagnostic category. Dialogues Clin Neurosci 2017;19(2):107–16. https://pubmed.ncbi.nlm.nih.gov/28867935/.CrossRefGoogle ScholarPubMed
Berger, A, Dukes, E, Wittchen, H-U, et al. Patterns of healthcare utilization in patients with generalized anxiety disorder in general practice in Germany. Eur J Psychiatry 2009;23(2).CrossRefGoogle Scholar
Wittchen, H-U. Generalized anxiety disorder: Prevalence, burden, and cost to society. Depress Anxiety 2002;16(4):162–71. https://onlinelibrary.wiley.com/doi/full/10.1002/da.10065.CrossRefGoogle ScholarPubMed
Sanderson, WC, Barlow, DH. A description of patients diagnosed with DSM-III-R generalized anxiety disorder. J Nerv Ment Dis 1990;178(9):588–91.CrossRefGoogle ScholarPubMed
Starcevic, V. Anxiety states: A review of conceptual and treatment issues. Curr Opin Psychiatry 2006;19(1):79–83. https://pubmed.ncbi.nlm.nih.gov/16612184/.CrossRefGoogle Scholar
Yonkers, K, Bruce, S, Dyck, I, Keller, M. Chronicity, relapse, and illness–course of panic disorder, social phobia, and generalized anxiety disorder: Findings in men and women from 8 years of follow-up. Depress Anxiety 2003;17(3):173–9. https://pubmed.ncbi.nlm.nih.gov/12768651/.CrossRefGoogle ScholarPubMed
Ravindran, LN, Stein, MB. Anxiety disorders: Somatic treatment. In Sadock, BJ, Sadock, VA, Ruiz, P (Eds.) Kaplan & Sadock Comprehensive Textbook of Psychiatry. Wolters Kluwer; 2009. pp. 1906–14.Google Scholar
Reinhold, JA, Rickels, K. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin Pharmacother 2015;16(11):1669–81.CrossRefGoogle ScholarPubMed
Kapczinski, F, dos Santos Souza, JJ, Batista Miralha da Cunha, AA, Schmitt, RR. Antidepressants for generalised anxiety disorder (GAD). In Kapczinski, F (Ed.). Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 2003.Google Scholar
Taylor, WD. Depression in the Elderly. N Engl J Med 2014;371(13):1228–36. https://doi.org/10.1056/NEJMcp1402180.CrossRefGoogle ScholarPubMed
Gommoll, C, Durgam, S, Mathews, M, et al. A double-blind, randomized, placebo-controlled, fixed dose phase III study of Vilazodone in patients with Generalized Anxiety Disorder. Depress Anxiety 2015;32(6):451–9.CrossRefGoogle ScholarPubMed
Chessick, CA, Allen, MH, Thase, ME, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006;3:CD006115.Google Scholar
Baldwin, DS, den Boer, JA, Lyndon, G, et al. Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. J Psychopharmacol 2015;29(10):1047–60.CrossRefGoogle ScholarPubMed
Kreys, T-JM, Phan, S V. A literature review of quetiapine for generalized anxiety disorder. Pharmacother J Hum Pharmacol Drug Ther 2015;35(2):175–88.CrossRefGoogle ScholarPubMed
Ravindran, LN, Stein, MB. The pharmacologic treatment of anxiety disorders. J Clin Psychiatry 2010;71(7):839–54.CrossRefGoogle ScholarPubMed
Billioti de Gage, S, Pariente, A, Bégaud, B. Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf 2015;14(5):733–47.CrossRefGoogle ScholarPubMed
Cuijpers, P, van Straten, A. Improving outcomes in social anxiety disorder. The Lancet Psychiatry. 2014;1(5):324–6. https://pubmed.ncbi.nlm.nih.gov/26360985/.CrossRefGoogle ScholarPubMed
Janet, P, Raymond, F. Les obsessions et la psychasthénie. Paris: Alcan; 1903. www.worldcat.org/title/obsessions-et-la-psychasthenie/oclc/5949962.Google Scholar
Rose, GM, Tadi, P. Social anxiety disorder. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021. Available from: www.ncbi.nlm.nih.gov/books/NBK555890/.Google Scholar
Scaini, S, Belotti, R, Ogliari, A. Genetic and environmental contributions to social anxiety across different ages: A meta-analytic approach to twin data. J Anxiety Disord 2014;28(7):650–6. https://pubmed.ncbi.nlm.nih.gov/25118017/.CrossRefGoogle Scholar
Leichsenring, F, Leweke, F. Social anxiety disorder. N Engl J Med 2017;376(23):2255–64. www.nejm.org/doi/10.1056/NEJMcp1614701.CrossRefGoogle ScholarPubMed
Hyett, MP, McEvoy, PM. Social anxiety disorder: Looking back and moving forward. Psychol Med 2018;48(12):1937–44. https://pubmed.ncbi.nlm.nih.gov/29321077/.CrossRefGoogle ScholarPubMed
Heimberg, RG, Hofmann, SG, Liebowitz, MR, et al. Social anxiety disorder in DSM-5. Depress Anxiety 2014;31(6):472–9. https://pubmed.ncbi.nlm.nih.gov/24395386/.CrossRefGoogle ScholarPubMed
Bögels, SM, Alden, L, Beidel, DC, et al. Social anxiety disorder: Questions and answers for the DSM-V. Depress Anxiety 2010;27(2):168–89. https://pubmed.ncbi.nlm.nih.gov/20143427/.CrossRefGoogle ScholarPubMed
Beidel, DC, Turner, SM, Sallee, FR, et al. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry 2007;46(12):1622–32. https://pubmed.ncbi.nlm.nih.gov/18030084/.CrossRefGoogle ScholarPubMed
Stein, MB, Stein, DJ. Social anxiety disorder. The Lancet 2008;371(9618):1115–25. https://pubmed.ncbi.nlm.nih.gov/18374843/.CrossRefGoogle ScholarPubMed
Steinert, C, Hofmann, M, Leichsenring, F, Kruse, J. What do we know today about the prospective long-term course of social anxiety disorder? A systematic literature review. J Anxiety Disord 2013;27(7):692–702. https://pubmed.ncbi.nlm.nih.gov/24176803/.CrossRefGoogle ScholarPubMed
Kashdan, T, Hofmann, S. The high-novelty-seeking, impulsive subtype of generalized social anxiety disorder. Depress Anxiety 2008;25(6):535–41. https://pubmed.ncbi.nlm.nih.gov/17935217/.CrossRefGoogle ScholarPubMed
D’Avanzato, C, Dalrymple, K. Recent Insight Into the Subtypes of Social Anxiety Disorder. Curr Psychiatry Rep 2016;18(5):50. https://pubmed.ncbi.nlm.nih.gov/27017831/.CrossRefGoogle ScholarPubMed
Nagata, T, Suzuki, F, Teo, AR. Generalized social anxiety disorder: A still-neglected anxiety disorder 3 decades since Liebowitz’s review. Psych Clin Neurosci 2015;69(12):724–40. https://pubmed.ncbi.nlm.nih.gov/26121185/.CrossRefGoogle Scholar
Ruscio, AM, Brown, TA, Chiu, WT, et al. Social fears and social phobia in the USA: Results from the National Comorbidity Survey Replication. Psychol Med 2008;38 (1):15–28. https://pubmed.ncbi.nlm.nih.gov/17976249/.CrossRefGoogle ScholarPubMed
Koyuncu, A, İnce, E, Ertekin, E, Tükel, R. Comorbidity in social anxiety disorder: Diagnostic and therapeutic challenges. Drugs in Context 2019;8:212573. https://pubmed.ncbi.nlm.nih.gov/30988687/CrossRefGoogle ScholarPubMed
Kessler, RC. The impairments caused by social phobia in the general population: Implications for intervention. Acta Psych Scand, Suppl 2003;417:19–27. https://pubmed.ncbi.nlm.nih.gov/12950433/.CrossRefGoogle Scholar
Mayo-Wilson, E, Dias, S, Mavranezouli, I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: A systematic review and network meta-analysis. The Lancet Psychiatry 2014;1(5):368–76. https://pubmed.ncbi.nlm.nih.gov/26361000/.CrossRefGoogle ScholarPubMed
Fedoroff, IC, Taylor, S. Psychological and pharmacological treatments of social phobia: A meta-analysis. J Clin Psychopharmacol 2001;21(3):311–24. https://pubmed.ncbi.nlm.nih.gov/11386495/.CrossRefGoogle ScholarPubMed
Canton, J, Scott, KM, Glue, P. Optimal treatment of social phobia: Systematic review and meta-analysis. Neuropsychiatr Dis Treat 2012;8:203–15. https://pubmed.ncbi.nlm.nih.gov/22665997/.Google ScholarPubMed
Lader, M, Stender, K, Bürger, V, Nil, R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19(4:241–8.CrossRefGoogle ScholarPubMed
Kasper, S, Stein, DJ, Loft, H, Nil, R. Escitalopram in the treatment of social anxiety disorder. Br J Psychiatry 2005;186(3):222–6.CrossRefGoogle ScholarPubMed
Van Ameringen, MA, Lane, RM, et al. Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001;158(2):275–81.CrossRefGoogle ScholarPubMed
Liebowitz, MR, DeMartinis, NA, Weihs, K, et al. Efficacy of sertraline in severe generalized social anxiety disorder. J Clin Psychiatry 2003;64(7):785–92.CrossRefGoogle ScholarPubMed
Allgulander, C, Mangano, R, Zhang, J, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol Clin Exp. 2004;19(6):387–96.CrossRefGoogle Scholar
Stein, MB, Pollack, MH, Bystritsky, A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmacology (Berl). 2005;177(3):280–8.CrossRefGoogle ScholarPubMed
Feltner, DE, Liu-Dumaw, M, Schweizer, E, Bielski, R. Efficacy of pregabalin in generalized social anxiety disorder. Int Clin Psychopharmacol. 2011;26(4):213–20.CrossRefGoogle ScholarPubMed
Worthington, EL, vanOyen Witvliet, C, Lerner, AJ, Scherer, M. Forgiveness in health research and medical practice. Explor J Sci Heal 2005;1(3):169–76. https://pubmed.ncbi.nlm.nih.gov/16781526/.Google ScholarPubMed
Sepede, G, De Berardis, D, Gambi, F, et al. Olanzapine augmentation in treatment-resistant panic disorder: A 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol 2006;26(1):45–9. https://pubmed.ncbi.nlm.nih.gov/16415705/.CrossRefGoogle ScholarPubMed
Van Ameringen, M, Mancini, C, Wilson, C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996;39(2):115–21. https://pubmed.ncbi.nlm.nih.gov/8827420/.CrossRefGoogle ScholarPubMed
Taylor, S. Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry 1996;27(1):1–9.CrossRefGoogle ScholarPubMed
Stangier, U, Heidenreich, T, Peitz, M, Lauterbach, W, Clark, DM. Cognitive therapy for social phobia: Individual versus group treatment. Behav Res Ther 2003;41(9):991–1007. https://pubmed.ncbi.nlm.nih.gov/12914803/.CrossRefGoogle ScholarPubMed
Mörtberg, E, Clark, DM, Sundin, Ö, Åberg Wistedt, A. Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: A randomized controlled trial. Acta Psychiatr Scand 2007;115(2):142–54. https://pubmed.ncbi.nlm.nih.gov/17244178/.CrossRefGoogle ScholarPubMed
Acarturk, C, Cuijpers, P, Van Straten, A, De Graaf, R. Psychological treatment of social anxiety disorder: A meta-analysis. Psychol Med 2009;39(2):241–54. https://pubmed.ncbi.nlm.nih.gov/18507874/.CrossRefGoogle ScholarPubMed
Titov, N, Andrews, G, Schwencke, G, Drobny, J, Einstein, D. Shyness 1: Distance treatment of social phobia over the internet. Aust New Zeal J Psychiatry 2008;42(7):585–94.Google Scholar
Berger, T, Hohl, E, Caspar, F. Internet-based treatment for social phobia: A randomized controlled trial. J Clin Psychol 2009;65(10):1021–35.CrossRefGoogle ScholarPubMed
Furmark, T. Neurobiological aspects of social anxiety disorder. Isr J Psychiatry Relat Sci 2009;46(1):5–12. https://pubmed.ncbi.nlm.nih.gov/19728568/.Google ScholarPubMed
Andrews, G, Davies, M, Titov, N. Effectiveness randomized controlled trial of face to face versus internet cognitive behaviour therapy for social phobia. Aust New Zeal J Psychiatry 2011;45(4):337–40.Google ScholarPubMed
Hedman, E, Furmark, T, Carlbring, P, et al. A 5-year follow-up of internet-based cognitive behavior therapy for social anxiety disorder. J Med Internet Res 2011;13(2):e39. https://pubmed.ncbi.nlm.nih.gov/21676694/.CrossRefGoogle ScholarPubMed
Otto, MW, Pollack, MH, Gould, RA, et al. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord 2000;14(4):345–58. https://pubmed.ncbi.nlm.nih.gov/11043885/.CrossRefGoogle ScholarPubMed
Clark, DM, Ehlers, A, McManus, F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: A randomized placebo-controlled trial. J Consult Clin Psychol 2003;71(6):1058–67. https://pubmed.ncbi.nlm.nih.gov/14622081/.CrossRefGoogle ScholarPubMed
Davidson, JRT, Foa, EB, Huppert, JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placeboin generalized social phobia. Arch Gen Psychiatry 2004;61(10):1005–13.CrossRefGoogle Scholar
Gomez, AF, Barthel, AL, Hofmann, SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: A meta-analytic review. Expert Opin Pharmacother 2018;19(8):883–94. https://pubmed.ncbi.nlm.nih.gov/29806492/CrossRefGoogle ScholarPubMed
Maron, E, Nutt, D. Biological predictors of pharmacological therapy in anxiety disorders. Dialogues Clin Neurosci 2015;17(3):305–17. https://pubmed.ncbi.nlm.nih.gov/26487811/.CrossRefGoogle ScholarPubMed
Koen, N, Stein, DJ. Pharmacotherapy of anxiety disorders: A critical review. Dialogues Clin Neurosci 2011;13(4):423–37. https://pubmed.ncbi.nlm.nih.gov/22275848/.CrossRefGoogle ScholarPubMed
Dell’Osso, B, Buoli, M, Baldwin, DS, Altamura, AC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: A comprehensive review of their clinical efficacy. Hum Psychopharmacol 2010;25(1):17–29. https://pubmed.ncbi.nlm.nih.gov/20041476/.CrossRefGoogle ScholarPubMed
Prendes-Alvarez, S, Nemeroff, CB. Personalized medicine: Prediction of disease vulnerability in mood disorders. Neurosci Lett 2018;669:10–13. https://pubmed.ncbi.nlm.nih.gov/27746310/.CrossRefGoogle ScholarPubMed
Vismara, M, Girone, N, Cirnigliaro, G, et al. Peripheral biomarkers in DSM-5 anxiety disorders: An updated overview. Brain Sciences 2020;10(8):564.CrossRefGoogle Scholar
Kim, Y-K. (Ed.) Anxiety Disorders. Springer Singapore; 2020. http://link.springer.com/10.1007/978-981-32-9705-0.CrossRefGoogle ScholarPubMed
Bandelow, B, Baldwin, D, Abelli, M, et al. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry 2017;18(3):162–214. https://pubmed.ncbi.nlm.nih.gov/27419272/.CrossRefGoogle ScholarPubMed
Niculescu, AB, Levey, D, Le-Niculescu, H, et al. Psychiatric blood biomarkers: Avoiding jumping to premature negative or positive conclusions. Mol Psychiatry 2015;20(3):286–8. https://pubmed.ncbi.nlm.nih.gov/25582618/.CrossRefGoogle ScholarPubMed
Quevedo, J, Yatham, LN. Biomarkers in mood disorders: Are we there yet? Vol. 233, J Affect Disord 2018;233:1–2. https://pubmed.ncbi.nlm.nih.gov/29395259/.CrossRefGoogle ScholarPubMed
Massaro, AR, Scivoletto, G, Tonali, P. Cerebrospinal fluid markers in neurological disorders. Ital J Neurol Sci 1990;11(6):537–47. https://pubmed.ncbi.nlm.nih.gov/1707039/.CrossRefGoogle ScholarPubMed
Juruena, MF, Eror, F, Cleare, AJ, Young, AH. The role of early life stress in HPA axis and anxiety. Adv Exp Med Biol 2020;1191:141–53.CrossRefGoogle ScholarPubMed
Faravelli, C, Lo Sauro, C, Lelli, L, et al. The Role of Life Events and HPA Axis in Anxiety Disorders: A Review. Curr Pharm Des 2012;18(35):5663–74.CrossRefGoogle ScholarPubMed
Gould, TD, Gottesman, II. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav 2006;5(2):113–19. https://pubmed.ncbi.nlm.nih.gov/16507002/.CrossRefGoogle ScholarPubMed
Gottesman, II, Gould, TD. The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry 2003;160(4):636–45. https://pubmed.ncbi.nlm.nih.gov/12668349/.CrossRefGoogle ScholarPubMed
Perna, G, Cocchi, S, Bertani, A, Arancio, C, Bellodi, L. Sensitivity to 35% CO2 in healthy first-degree relatives of patients with panic disorder. Am J Psychiatry 1995;152(4):623–5. https://pubmed.ncbi.nlm.nih.gov/7694916/.Google ScholarPubMed
Battaglia, M, Perna, G. The 35% CO2 challenge in panic disorder: Optimization by receiver operating characteristic (ROC) analysis. J Psychiatr Res. 1995;29(2):111–19.CrossRefGoogle ScholarPubMed
do Amaral, JMX, Spadaro, PTM, Pereira, VM, et al. The carbon dioxide challenge test in panic disorder: A systematic review of preclinical and clinical research. Revista Brasileira de Psiquiatria 2013;35(3):318–31.Google Scholar
Perna, G, Bussi, R, Allevi, L, Bellodi, L. Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. J Clin Psychiatry. 1999;60(6):379–84.CrossRefGoogle ScholarPubMed
Verburg, K, Griez, E, Meijer, J, Pols, H. Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. Am J Psychiatry 1995;152(7):1081–3. https://pubmed.ncbi.nlm.nih.gov/7793449/.Google ScholarPubMed
Bertani, A, Caldirola, D, Bussi, R, Bellodi, L, Perna, G. The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: An open study. J Clin Psychopharmacol 2001;21(3):262–7. https://pubmed.ncbi.nlm.nih.gov/11386488/.CrossRefGoogle ScholarPubMed
Perna, G, Bertani, A, Caldirola, D, et al. Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome. J Clin Psychopharmacol. 2002;22(3):300–8.CrossRefGoogle ScholarPubMed
Perna, G, Bertani, A, Gabriele, A, Politi, E, Bellodi, L. Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: A double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 1997;17(3):173–8. https://pubmed.ncbi.nlm.nih.gov/9169961/.CrossRefGoogle ScholarPubMed
Perna, G, Bertani, A, Caldirola, D, et al. Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: A double-blind, randomized study. J Clin Psychopharmacol 2004;24(3):277–82. https://pubmed.ncbi.nlm.nih.gov/15118481/.CrossRefGoogle ScholarPubMed
Eriksson, E, Westberg, P, Alling, C, Thuresson, K, Modigh, K. Cerebrospinal fluid levels of monoamine metabolites in panic disorder. Psychiatry Res 1991;36(3):243–51. https://pubmed.ncbi.nlm.nih.gov/1712114/.CrossRefGoogle ScholarPubMed
Cosci, F, Mansueto, G. Biological and clinical markers in panic disorder. Psychiat Investigation 2019;16(1):27–36. https://pubmed.ncbi.nlm.nih.gov/30184613/.CrossRefGoogle ScholarPubMed
Bhad, R. Editorial: Red blood cell and platelet indices: A potential biomarker for panic disorder. J Neurosci Rural Pract 2017;8(2):164. https://pubmed.ncbi.nlm.nih.gov/28479785/.Google ScholarPubMed
Quagliato, LA, Nardi, AE. Cytokine alterations in panic disorder: A systematic review. J Affect Disord. 2018;228:91–6. https://pubmed.ncbi.nlm.nih.gov/29241050/.CrossRefGoogle ScholarPubMed
Iny, LJ, Pecknold, J, Suranyi-Cadotte, BE, et al. Studies of a neurochemical link between depression, anxiety, and stress from [3 H]imipramine and [3 H]paroxetine binding on human platelets. Biol Psychiatry 1994;36(5):251–91. https://pubmed.ncbi.nlm.nih.gov/7993954/.CrossRefGoogle ScholarPubMed
Hernández, E, Lastra, S, Urbina, M, Carreira, I, Lima, L. Serotonin, 5-hydroxyindoleacetic acid and serotonin transporter in blood peripheral lymphocytes of patients with generalized anxiety disorder. Int Immunopharmacol 2002;2(7):893–900. https://pubmed.ncbi.nlm.nih.gov/12188031/.CrossRefGoogle ScholarPubMed
Phillips, AC, Batty, GD, Gale, CR, et al. Major depressive disorder, generalised anxiety disorder, and their comorbidity: Associations with cortisol in the Vietnam Experience Study. Psychoneuroendocrinology 2011;36(5):682–90. https://pubmed.ncbi.nlm.nih.gov/20952132/.CrossRefGoogle ScholarPubMed
Molendijk, ML, Bus, BAA, Spinhoven, P, et al. Gender specific associations of serum levels of brain-derived neurotrophic factor in anxiety. World J Biol Psychiatry 2012;13(7):535–43. https://pubmed.ncbi.nlm.nih.gov/21888560/.CrossRefGoogle ScholarPubMed
Bankier, B, Barajas, J, Martinez-Rumayor, A, Januzzi, JL. Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients. Eur Heart J 2008;29(18):2212–17. https://pubmed.ncbi.nlm.nih.gov/18603621/.CrossRefGoogle ScholarPubMed
Copeland, WE, Shanahan, L, Worthman, C, Angold, A, Costello, EJ. Generalized anxiety and C-reactive protein levels: A prospective, longitudinal analysis. Psychol Med 2012;42(12):2641–50. https://pubmed.ncbi.nlm.nih.gov/22716910/CrossRefGoogle Scholar
Marazziti, D, Abelli, M, Baroni, S, et al. Neurobiological correlates of social anxiety disorder: An update. CNS Spectrums 2015;20(2):100–11. https://pubmed.ncbi.nlm.nih.gov/24571962/.CrossRefGoogle ScholarPubMed
van Honk, J, Bos, PA, Terburg, D, Heany, S, Stein, DJ. Neuroendocrine models of social anxiety disorder. Dialogues Clin Neurosci 2015;17(3):287–93. https://pubmed.ncbi.nlm.nih.gov/26487809/.CrossRefGoogle ScholarPubMed
Jones, C, Barrera, I, Brothers, S, Ring, R, Wahlestedt, C. Oxytocin and social functioning. Dialogues Clin Neurosci 2017;19(2):193–201. https://pubmed.ncbi.nlm.nih.gov/28867943/.CrossRefGoogle ScholarPubMed
Giltay, EJ, Enter, D, Zitman, FG, et al. Salivary testosterone: Associations with depression, anxiety disorders, and antidepressant use in a large cohort study. J Psychosom Res 2012;72(3):205–13. https://pubmed.ncbi.nlm.nih.gov/22325700/.CrossRefGoogle Scholar
Hoge, EA, Lawson, EA, Metcalf, CA, et al. Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder. Depress Anxiety 2012;29(11):924–30. https://pubmed.ncbi.nlm.nih.gov/22807189/.CrossRefGoogle ScholarPubMed
Ressler, KJ, Nemeroff, CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000;12:2–19.3.0.CO;2-4>CrossRefGoogle ScholarPubMed
Johnson, MR, Lydiard, RB. The neurobiology of anxiety disorders. Psychiatric Clinics of North America 1995; 18: 681–725.CrossRefGoogle ScholarPubMed
McNaughton, N, Corr, PJ. A two-dimensional neuropsychology of defense: Fear/anxiety and defensive distance. Neurosci Biobehav Rev 2004; 28:285–305. https://pubmed.ncbi.nlm.nih.gov/15225972/.CrossRefGoogle ScholarPubMed
Moreira, FP, Fabião, JD, Bittencourt, G, et al. The Met allele of BDNF Val66 Met polymorphism is associated with increased BDNF levels in generalized anxiety disorder. Psychiatr Genet 2015;25(5):201–17. https://pubmed.ncbi.nlm.nih.gov/26110341/.CrossRefGoogle Scholar
Lin, M, Zhu, J, Yuan, Y, et al. Association analysis of the brain-derived neurotrophic factor gene val66 met polymorphism and gender with efficacy of antidepressants in the Chinese Han population with generalized anxiety disorder. Genet Test Mol Biomarkers 2018;22(3):199–206. https://pubmed.ncbi.nlm.nih.gov/29446659/.CrossRefGoogle Scholar
Maron, E, Tõru, I, Must, A, et al. Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder. Neurosci Lett 2007;411(3):180–4. https://pubmed.ncbi.nlm.nih.gov/17123728/.CrossRefGoogle ScholarPubMed
Domschke, K, Deckert, J, O’Donovan, MC, Glatt, SJ. Meta-analysis of COMT val158 met in panic disorder: Ethnic heterogeneity and gender specificity. Am J Med Genet Part B Neuropsychiatr Genet 2007;144(5):667–73. https://pubmed.ncbi.nlm.nih.gov/17357147/.Google Scholar
Spence, SH, Rapee, RM. The etiology of social anxiety disorder: An evidence-based model. Behaviour Research and Therapy. 2016;86: 50–67. https://pubmed.ncbi.nlm.nih.gov/27406470/.CrossRefGoogle ScholarPubMed
Bergman, O, Åhs, F, Furmark, T, et al. Association between amygdala reactivity and a dopamine transporter gene polymorphism. Transl Psychiatry 2014;4(8). https://pubmed.ncbi.nlm.nih.gov/25093598/.CrossRefGoogle Scholar
Domschke, K, Stevens, S, Beck, B, et al. Blushing propensity in social anxiety disorder: Influence of serotonin transporter gene variation. J Neural Transm 2009;116(6):663–6. https://pubmed.ncbi.nlm.nih.gov/18629430/.CrossRefGoogle ScholarPubMed
Perna, G, Favaron, E, Di Bella, D, Bussi, R, Bellodi, L. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 2005;30(12):2230–5. https://pubmed.ncbi.nlm.nih.gov/16034444/.CrossRefGoogle ScholarPubMed
Schiele, MA, Domschke, K. Epigenetics at the crossroads between genes, environment and resilience in anxiety disorders. Genes Brain Behav 2018;17(3):e12423. https://pubmed.ncbi.nlm.nih.gov/28873274/.CrossRefGoogle ScholarPubMed
Schartner, C, Ziegler, C, Schiele, MA, et al. CRHR1 promoter hypomethylation: An epigenetic readout of panic disorder? Eur Neuropsychopharmacol 2017;27(4):360–71. https://pubmed.ncbi.nlm.nih.gov/28233670/.CrossRefGoogle ScholarPubMed
Domschke, K, Tidow, N, Schrempf, M, et al. Epigenetic signature of panic disorder: A role of glutamate decarboxylase 1 (GAD1) DNA hypomethylation? Prog Neuro-Psychopharmacology Biol Psychiatry 2013;46:189–96. https://pubmed.ncbi.nlm.nih.gov/23906988/.CrossRefGoogle ScholarPubMed
Ziegler, C, Dannlowski, U, Bräuer, D, et al. Oxytocin receptor gene methylation: Converging multilevel evidence for a role in social anxiety. Neuropsychopharmacology 2015;40(6):1528–38. https://pubmed.ncbi.nlm.nih.gov/25563749/.CrossRefGoogle ScholarPubMed
Won, E, Kim, YK. Neuroinflammation‐associated alterations of the brain as potential neural biomarkers in anxiety disorders. Int J Mol Sci 2020;21(18):1–19. https://pubmed.ncbi.nlm.nih.gov/32906843/.CrossRefGoogle ScholarPubMed
Bas-Hoogendam, JM, Groenewold, NA, Aghajani, M, et al. ENIGMA-anxiety working group: Rationale for and organization of large-scale neuroimaging studies of anxiety disorders Human Brain Mapping 2020;43(1):83–112. https://pubmed.ncbi.nlm.nih.gov/32618421/.CrossRefGoogle Scholar
Gorman, JM, Kent, JM, Sullivan, GM, Coplan, JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493–505. https://pubmed.ncbi.nlm.nih.gov/10739407/.CrossRefGoogle ScholarPubMed
Engel, KR, Obst, K, Bandelow, B, et al. Functional MRI activation in response to panic-specific, non-panic aversive, and neutral pictures in patients with panic disorder and healthy controls. Eur Arch Psychiatry Clin Neurosci 2016;266(6):557–66. https://pubmed.ncbi.nlm.nih.gov/26585457/.CrossRefGoogle ScholarPubMed
Sobanski, T, Wagner, G. Functional neuroanatomy in panic disorder: Status quo of the research. World J Psychiatry 2017;7(1):12. https://pubmed.ncbi.nlm.nih.gov/28401046/.CrossRefGoogle ScholarPubMed
Perna, G, Guerriero, G, Brambilla, P, Caldirola, D. Panic and the brainstem: Clues from neuroimaging studies. CNS Neurol Disord – Drug Targets 2014;13(6):1049–56. https://pubmed.ncbi.nlm.nih.gov/24923341/.CrossRefGoogle ScholarPubMed
Shin, LM, Davis, F, VanElzakker, MB, Dahlgren, MK, Dubois, SJ. Neuroimaging predictors of treatment response in anxiety disorders. Biol Mood Anxiety Disord 2013;3(1):15. https://pubmed.ncbi.nlm.nih.gov/23915782/.CrossRefGoogle ScholarPubMed
Santos, VA, Carvalho, DD, Van Ameringen, M, Nardi, AE, Freire, RC. Neuroimaging findings as predictors of treatment outcome of psychotherapy in anxiety disorders. Prog Neuro-Psychopharmacol Biol Psychiatry 2019;91:60–71. https://pubmed.ncbi.nlm.nih.gov/29627509/.CrossRefGoogle ScholarPubMed
Etkin, A, Prater, KE, Schatzberg, AF, Menon, V, Greicius, MD. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry 2009;66(12):1361–72. https://pubmed.ncbi.nlm.nih.gov/19996041/.CrossRefGoogle ScholarPubMed
Liao, M, Yang, F, Zhang, Y, et al. Childhood maltreatment is associated with larger left thalamic gray matter volume in adolescents with generalized anxiety disorder. PLoS One 2013;8(8):e71898. https://pubmed.ncbi.nlm.nih.gov/23951265/.CrossRefGoogle ScholarPubMed
Hilbert, K, Pine, DS, Muehlhan, M, et al. Gray and white matter volume abnormalities in generalized anxiety disorder by categorical and dimensional characterization. Psychiatry Res – Neuroimaging 2015;234(3):314–20. https://pubmed.ncbi.nlm.nih.gov/26490569/.CrossRefGoogle ScholarPubMed
Makovac, E, Meeten, F, Watson, DR, et al. Neurostructural abnormalities associated with axes of emotion dysregulation in generalized anxiety. NeuroImage Clin 2016;10:172–81. https://pubmed.ncbi.nlm.nih.gov/26759791/.CrossRefGoogle ScholarPubMed
Schienle, A, Ebner, F, Schäfer, A. Localized gray matter volume abnormalities in generalized anxiety disorder. Eur Arch Psychiatry Clin Neurosci 2011;261(4):303–7. https://pubmed.ncbi.nlm.nih.gov/20820793/.CrossRefGoogle ScholarPubMed
Whalen, PJ, Johnstone, T, Somerville, LH, et al. A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biol Psychiatry 2008;63(9):858–63. https://pubmed.ncbi.nlm.nih.gov/17964548/.CrossRefGoogle ScholarPubMed
Nitschke, JB, Sarinopoulos, I, Oathes, DJ, et al. Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry 2009;166(3):302–10. https://pubmed.ncbi.nlm.nih.gov/19122007/.CrossRefGoogle ScholarPubMed
Ball, TM, Stein, MB, Ramsawh, HJ, et al. Single-subject anxiety treatment outcome prediction using functional neuroimaging. Neuropsychopharmacology 2014;39(5):1254–61. https://pubmed.ncbi.nlm.nih.gov/24270731/.CrossRefGoogle ScholarPubMed
Cremers, HR, Roelofs, K. Social anxiety disorder: A critical overview of neurocognitive research. Wiley Interdiscip Rev Cogn Sci 2016 ;7(4):218–32. https://pubmed.ncbi.nlm.nih.gov/27240280/.CrossRefGoogle ScholarPubMed
Klumpp, H, Fitzgerald, JM. Neuroimaging predictors and mechanisms of treatment response in social anxiety disorder: An overview of the amygdala. Curr Psychiatry Rep 2018;20(10):89. https://pubmed.ncbi.nlm.nih.gov/30155657/.CrossRefGoogle ScholarPubMed
Liu, S, Li, E, Sun, Z, et al. Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder. Sci Rep 2019;9(1):287. https://pubmed.ncbi.nlm.nih.gov/30670726/.CrossRefGoogle ScholarPubMed
Jiang, H, Ling, Z, Zhang, Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun 2015;48:186–94. https://pubmed.ncbi.nlm.nih.gov/25882912/.CrossRefGoogle ScholarPubMed
Schwarz, E, Maukonen, J, Hyytiäinen, T, et al. Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response. Schizophr Res 2018;192:398–403. https://pubmed.ncbi.nlm.nih.gov/28442250/.CrossRefGoogle ScholarPubMed
Evans, S, Bassis, C, Hein, R, et al. The gut microbiome composition associates with bipolar disorder and illness severity. J Psychiatr Res 2017;87:23–9. https://pubmed.ncbi.nlm.nih.gov/27988330/.CrossRefGoogle ScholarPubMed
Keller, J, Gomez, R, Williams, G, et al. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol Psychiatry 2017;22(4):527–36. https://pubmed.ncbi.nlm.nih.gov/27528460/.CrossRefGoogle ScholarPubMed
Winter, G, Hart, R, Charlesworth, R, Sharpley, C. Gut microbiome and depression: What we know and what we need to know. Rev Neurosci 2018;29(6):629–43. https://pubmed.ncbi.nlm.nih.gov/29397391/.CrossRefGoogle ScholarPubMed
Mayer, E, K T, Gupta, A. Gut/brain axis and the microbiota. J Clin Invest 2015;125(3):926–38. https://pubmed.ncbi.nlm.nih.gov/25689247/.CrossRefGoogle ScholarPubMed
Mayer, E, Knight, R, Mazmanian, S, Cryan, J, Tillisch, K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci 2014;34(46):15490–6. https://pubmed.ncbi.nlm.nih.gov/25392516/.CrossRefGoogle ScholarPubMed
Chen, Y, Bai, J, Wu, D, et al. Association between fecal microbiota and generalized anxiety disorder: Severity and early treatment response. J Affect Disord 2019;259:56–66. https://pubmed.ncbi.nlm.nih.gov/31437702/.CrossRefGoogle ScholarPubMed
Bangsgaard Bendtsen, K, Krych, L, Sørensen, D, et al. Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse. PLoS One 2012;7(10). https://pubmed.ncbi.nlm.nih.gov/23056268/.CrossRefGoogle ScholarPubMed
Vemuri, R, Sylvia, K, Klein, S, et al. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin Immunopathol 2019;41(2):265–75. https://pubmed.ncbi.nlm.nih.gov/30298433/.CrossRefGoogle ScholarPubMed
Gibson-Smith, D, Bot, M, Brouwer, I, Visser, M, Penninx, B. Diet quality in persons with and without depressive and anxiety disorders. J Psychiatr Res 2018;106:1–7. https://pubmed.ncbi.nlm.nih.gov/30240962/.CrossRefGoogle ScholarPubMed
Simpson, C, Schwartz, O, Simmons, J. The human gut microbiota and depression: widely reviewed, yet poorly understood. J Affect Disord 2020;274:73–5. https://pubmed.ncbi.nlm.nih.gov/32469834/.CrossRefGoogle ScholarPubMed
Mörkl, S, Butler, M, Holl, A, Cryan, J, Dinan, T. Probiotics and the microbiota-gut-brain axis: Focus on psychiatry. Curr Nutr Rep 2020;9(3):171–82. https://pubmed.ncbi.nlm.nih.gov/32406013/.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×